Life Extension Bio-Fisetin
8 mg fisetin per capsule
Low-dose fisetin with fenugreek galactomannans.
Best for: reviewing a low-dose fisetin label in Key Facts
View on Amazon · Affiliate link
Evidence update: Trial registration and preliminary biomarkers are not proof of clinical benefit or successful senescent-cell clearance.
As of 2026, at least six registered human clinical trials are evaluating fisetin for aging-related outcomes. The most advanced, the PEARL trial (NCT02555878), evaluated fisetin 20 mg/kg/day × 2 days in older adults with adiposity and has reported preliminary positive findings on circulating senescence biomarkers. No significant adverse events have been reported across trials.
As an Amazon Associate, Stacking Years earns from qualifying purchases.
8 mg fisetin per capsule
Low-dose fisetin with fenugreek galactomannans.
Best for: reviewing a low-dose fisetin label in Key Facts
View on Amazon · Affiliate link
Are the fisetin trial results published?
Some preliminary data has been presented at aging research conferences (ICAD, AGS Annual Meeting) and included in grant renewal applications. Full peer-reviewed publications from PEARL are anticipated in 2025–2026.
Can I participate in a fisetin clinical trial?
Check ClinicalTrials.gov for open enrollment. Search "fisetin senolytic" or "fisetin aging." Many trials seek participants aged 65+ with specific health characteristics.
Do the clinical trials use the same supplement available commercially?
Trial-grade fisetin is pharmaceutical quality (>99% purity) sourced from regulated suppliers. Commercial supplements vary in purity from 50–98%+. Look for products certifying ≥98% fisetin content from third-party testing.
Fisetin research spans cell studies, animal experiments, and registered human studies, but registration is not evidence of a positive result. A trial registry records planned methods and status; it does not show that an intervention worked. Some small studies examine feasibility, safety, or biomarkers rather than outcomes such as memory, mobility, hospitalization, or survival. Claims of completed trials with proven senescent-cell clearance should be checked against a peer-reviewed report and its prespecified primary endpoint.
When evaluating a result, note the population, number randomized, comparator, duration, dose, dropouts, and whether the main endpoint was changed. A shift in a blood marker may not mean senescent cells were removed from a target organ. A short trial also cannot establish long-term safety. The current evidence does not support fisetin for Alzheimer’s prevention, frailty treatment, or lifespan extension.
FAQ — Should I copy a study dose? No. Trial procedures are designed for enrolled participants and are not general dosing advice.
Trial status: ClinicalTrials.gov fisetin search; registered safety study.